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Abstract: Since NLRP3 inflammasome plays a pivotal role in several neurodegenerative disorders,
we hypothesized that levels of inflammasome components could help in diagnosis or prognosis
of amyotrophic lateral sclerosis (ALS). Gene and protein expression was assayed by RT-PCR and
Western blot. Spearman’s correlation coefficient was used to determine the linear correlation of
transcriptional expression levels with longevity throughout disease progression in mice models.
Kaplan-Meier analysis was performed to evaluate MCC950 effects (NLRP3 inhibitor) on lifespan
of SOD1G93A mice. The results showed significant alterations in NLRP3 inflammasome gene
and protein levels in the skeletal muscle of SOD1G93A mice. Spearman’s correlation coefficient
revealed a positive association between Nlrp3 transcriptional levels in skeletal muscle and longevity
of SOD1G93A mice (r = 0.506; p = 0.027). Accordingly, NLRP3 inactivation with MCC950 decreased
the lifespan of mice. Furthermore, NLRP3 mRNA levels were significantly elevated in the blood of
ALS patients compared to healthy controls (p = 0.03). In conclusion, NLRP3 could be involved in
skeletal muscle pathogenesis of ALS, either through inflammasome or independently, and may play
a dual role during disease progression. NLRP3 gene expression levels could be used as a biomarker
to improve diagnosis and prognosis in skeletal muscle from animal models and also to support
diagnosis in clinical practice with the blood of ALS patients.
Keywords: neuroinflammation; NLRP3; inflammasome; biomarker; amyotrophic lateral sclerosis
(ALS); skeletal muscle; SOD1G93A; blood; ALS patients
1. Introduction
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by
atrophy and paralysis of voluntary muscles as a result of the progressive loss of upper
and lower motor neurons. Most cases of amyotrophic lateral sclerosis are sporadic (SALS),
and approximately 5–10% represents the familial form of the disease (familial amyotrophic
lateral sclerosis (FALS)), in which 20% have a SOD1 gene mutation. Although SALS
presents a low incidence (1.89 people per 100,000/year) and prevalence (5.2 people per
100,000), it is one of the most common neurodegenerative diseases. Unfortunately, patients
have an average lifespan of less than five years after the onset of the first symptoms, which
could pass unnoticed.
Current diagnostic procedures are based on a series of clinical criteria that on many
occasions are not able to establish a definitive diagnosis or determine the prognosis of
disease. For this reason, it is essential to improve the actual methods in order to start earlier
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palliative treatments and have greater control over disease progression, thus improving
both lifespan and quality of life as much as possible. During the last decades, a wide variety
of biomarkers have been studied in ALS involved in different molecular mechanisms that
inevitably lead to motor neuron degeneration (excitotoxicity, oxidative stress, mitochondrial
dysfunction, aggregation of misfolded proteins). However, today there is no sensitive and
specific molecular biomarker of ALS [1–3].
Whereas the central nervous system (CNS) has traditionally been considered an
immunologically privileged tissue, there is considerable evidence to support the presence
of immune and inflammatory abnormalities in ALS. Neuroinflammation, characterized by
activated microglia, astrogliosis and immune cell infiltration, is a prominent pathological
finding in the spinal cord of patients with ALS (both familial and sporadic) and in murine
models of the disease [4]. It has been seen that the main effector cells of neuroinflammation
interact in a context- and time-dependent manner, mediating both neuroprotective and
neurotoxic effects [5]. Thus, having this evidence that there is a local and systemic alteration
of the immune system in ALS, it is very important to characterize it in order to determine
if it is harmful or beneficial in the progression of the disease.
In the last years, it has been seen that neuroinflammation is mediated by cytosolic
protein complexes, known as inflammasomes, whose function is to act as intracellular
sensors to detect external signals (PAMPs, pathogen-associated molecular patterns) and
internal danger signals (DAMPs, damage-associated molecular patterns). The best char-
acterized inflammasome is NLRP3, which is composed of the NOD-like receptor pyrin
domain containing protein 3, the adaptor protein ASC and pro-caspase 1. Although it
has been shown that this inflammasome plays an important role in neurodegenerative
disorders, such as multiple sclerosis, Alzheimer’s disease and Parkinson’s disease, little is
known about its implication in ALS. Recently, several studies have shown the activation
of NLRP3 inflammasome in the brains of SOD1G93A mice [6], SOD1G93A rats [7] and
SALS patients [8] and also in the spinal cord of the SOD1G93A mouse model and SALS
patients [9]. However, its involvement in ALS has not been studied in depth and even
less in other tissues than CNS. Despite numerous studies that support the advantages and
benefits of therapies targeting skeletal muscle in ALS, it is still unknown if inflammation
occurs in muscle and near neuromuscular junctions, and how it could contribute to the
survival of motor neurons, neuromuscular innervation or motor dysfunction in ALS [10].
In light of all this, we hypothesized that NLRP3 inflammasome activation could en-
hance skeletal muscle degeneration in ALS, and that therefore, its components levels could
predict the disease progression. Thus, our main objective was to analyze in depth NLRP3 in-
flammasome expression and activation in this tissue in order to further understand muscle
pathology in ALS and provide an early diagnosis and prognosis for an efficient treatment.
The findings in this study revealed that NLRP3 may be involved in ALS pathogenesis
and that its gene expression levels could be used as a biomarker to improve diagnosis and
prognosis in skeletal muscle from mouse models and also to support diagnosis in blood
samples of ALS patients.
2. Results
2.1. NLRP3 Inflammasome Is Upregulated in Skeletal Muscle of SOD1G93A Mice
In order to investigate the activation of NLRP3 inflammasome in skeletal muscle, we
first analyzed the gene and protein levels of NLRP3 inflammasome components (NLRP3,
ASC, caspase 1 and IL1β) in the quadriceps of wild type (WT) and transgenic SOD1G93A
mice at the asymptomatic (P50), early symptomatic (P75) and terminal stage of the disease
(P120) (Figure 1).
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Figure 1. Expression levels of NLRP3 inflammasome in skeletal muscle of SOD1G93A mice during 
disease progression (P50: asymptomatic stage; P75: early symptomatic stage; P120: terminal stage). 
(A) Transcriptional levels of NLRP3 inflammasome components determined by real-time PCR in 
the quadriceps tissue. Dunnet’s post hoc test correction between groups also yielded statistically 
significant differences among groups at the asymptomatic stage (Asc, p = 0.037; caspase 1, p = 0.046; 
Il1β, p = 0.041). (B) Protein expression levels of NLRP3 components in quadriceps muscle deter-
mined by Western blotting. Dunnet’s post hoc test correction between groups also yielded statisti-
cally significant differences among groups at the terminal stage (NLRP3, p = 0.025; ASC, p = 0.007; 
pro-caspase 1, p = 0.003; pro-IL1β, p < 0.000). (C) Protein bands of each NLRP3 inflammasome 
component. Active caspase 1 and mature IL1β were only detected in SOD1G93A mice. The total 
number of animals used was 24 (8 mice for each stage: WT n = 4 and SOD1G93A n = 4). * p < 0.05, 
** p < 0.01; significant differences in comparison to WT mice. 
With respect to gene levels (Figure 1A), most of the transcriptional levels of inflam-
masome components were significantly elevated at P50 in SOD1G93A animals compared 
to WT, suggesting a possible activation of NLRP3 inflammasome at earlier stages. At P75 
Figure 1. Expression levels of NLRP3 inflammasome in skeletal muscle of SOD1G93A mice during
disease progression (P50: asymptomatic stage; P75: early symptomatic stage; P120: terminal stage).
(A) Transcriptional levels of NLRP3 inflammasome components determined by real-time PCR in
the quadriceps tissue. Dunnet’s post hoc test orrection between groups also yielded statistically
significant diff rences among groups at the asymptomatic stage (Asc, p = 0.037; caspase 1, p = 0.046;
Il1β, p = 0.041). (B) Protein expression levels of NLRP3 components in quadriceps muscle determined
by Western blotting. Dunnet’s post hoc test correction between groups also yielded statistically
significant differences among groups at the terminal stage (NLRP3, p = 0.025; ASC, p = 0.007; pro-
caspase 1, p = 0.003; pro-IL1β, p < 0.000). (C) Protein bands of each NLRP3 inflammasome component.
Active caspase 1 and m ture IL1β we e only detected in SOD1G93A mice. The total number of
animals used w s 24 (8 mice for each stage: WT n = 4 and SOD1G93A n = 4). * p < 0.05, ** p < 0.01;
significant differences in comparison to WT mice.
With respect to gene levels (Figur 1A), most of the transcriptional levels of inflam-
masome components wer significantly elevated at P50 in SOD1G93A animals compared
to WT, suggesting a possible activation of NLRP3 inflammasome at earlier stages. At P75
and P120 no significant differences were observed, except for caspase 1 levels that were
significantly increased in SOD1G93A animals compared to WT at P120.
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Regarding the protein expression levels, an opposed profile pattern was observed
(Figure 1B). The translational levels of inflammasome components were significantly
elevated at P120 in SOD1G93A animals compared to WT, while mean values tended to be
increased in all the components except for NLRP3, which was observed at P75.
Interestingly, mature IL1β and active caspase 1 were detectable in SOD1G93A animals,
but not in WT mice (Figure 1C). This would suggest that NLRP3 inflammasome is only
activated in skeletal muscle from ALS mouse models, especially during the terminal stage,
contributing thus to its pathology.
Consequently, our next step was to explore the prognostic nature of the NLRP3
inflammasome to validate its potential role during the disease progression.
2.2. Increased Transcriptional Levels of Nlrp3 in Skeletal Muscle at Earlier Stages Correlated with
a Higher Survival Rate in SOD1G93A Mice
Skeletal muscle serial biopsies were performed on transgenic SOD1G93A mice at three
disease stages: the early symptomatic (75 days), symptomatic (105 days) and endpoint
stages. In this last stage, the longevity of each animal was different (ranging between 120
and 160 days), and therefore we evaluated the possible correlation between the longevity
of the animals and the variation of the transcriptional levels during disease progression.
Among the four genes studied (Figure 2), the transcriptional levels of Nlrp3 were the
only ones that correlated significantly and positively with the longevity of the transgenic
SOD1G93A mice (r = 0.506, p = 0.027) (Figure 2A). This positive correlation suggested
that the animals that survived longer displayed higher transcriptional levels of this gene
during disease progression, especially between the early symptomatic and symptomatic
stages. Consequently, Nlrp3 could be considered a prognostic biomarker of longevity in
this animal model.
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Figure 2. Linear correlation graphs between longevity and transcriptional expression levels of NLRP3 inflammasome 
components throughout disease progression: (A) Nlrp3, (B) Asc, (C) caspase 1, (D) Il1β. Only Nlrp3 levels showed a signif-
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Figure 2. Linear correlation graphs between longevity and transcriptional expression levels of NLRP3 inflammasome
components throughout disease progression: (A) Nlrp3, (B) Asc, (C) caspase 1, (D) Il1β. Only Nlrp3 levels showed a
significant and positive correlation with longevity. The total number of transgenic SOD1G93A mice used was 20. Three
skeletal muscle biopsies were obtained per mouse, at different stages: early symptomatic stage (75 days), symptomatic
stage (105 days) and terminal stage (endpoint age).
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Contrary to our initial hypothesis, but in accordance with the M1/M2 paradigm in
inflammation, this finding showed that NLRP3 may exhibit an unexpected regenerative
capacity to compensate muscle damage induced by the neurodegenerative progression
of the disease, since the transgenic SOD1G93A mice that survived longer also exhibited
increased levels of this gene.
In view of these findings, our next step was to inactivate NLRP3 in this animal
model to elucidate whether NLRP3 certainly could induce a beneficial role during the
disease progression.
2.3. Inactivation of NLRP3 with MCC950 Exerted a Detrimental Effect on the Longevity of
SOD1G93A Mice
In order to determine the effect of NLRP3 on the longevity of SOD1G93A mice, twenty-
seven animals at age of 70 days (early symptomatic stage) were subjected to intraperitoneal
injections of MCC950 or PBS (control) three times per week until death.
MCC950 is a potent and selective inhibitor of NLRP3 which closes its active con-
formation to an inactive state, thus preventing the assembly and activation of NLRP3
inflammasome [11–13]. Considering the findings obtained previously with the longevity of
the mice, the inhibition of NLRP3 at the early symptomatic stage might enhance a shorter
lifespan in this animal model.
MCC950-treated mice exhibited a lower mean lifespan (113.571 days ± 18.48) com-
pared to untreated controls (128.692 days ± 7.54, log-rank test p = 0.025) (Figure 3), with
MCC950 treatment being particularly relevant in the early stages. Interestingly, this find-
ing is in accordance with the result obtained in our previous correlation study between
longevity and the transcriptional expression levels (Figure 2), thus supporting the hypoth-
esis that NLRP3 could exert a dual role in ALS pathogenesis with a compensatory and
beneficial effect at the beginning of the disease.
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Figure 3. K plan–Meier analysis of the e fect of MCC950 drug on survival rate. Non-treated
transgenic SOD1G93A mice showed a longer lifesp n (128.692 days ± 7.54) han MCC950-treated
mice (113.571 days ± 18.48); log-rank test p = 0.025. The total number of animals used was 27 (control
n = 13 and MCC950 treatment n = 14).
2.4. Potential Support for Diagnosis Role of NLRP3 in Blood Samples from ALS Patients
Based on the findings obtained in the animal model, we aimed to translate this study
to blood samples from ALS patients and to investigate the role of NLRP3 as a potential
support for diagnosis biomarker in these samples.
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We studied, by real-time PCR, the differences in NLRP3 gene expression profiles
between three different groups: healthy subjects (control), ALS patients and patients with
other myopathies (OMP) (Table 1).
Table 1. General and Clinical Characteristics of the Participants in the Blood Study Cohort.





Gender (n) 9 males 10 males 6 males5 females 4 females 8 females
Age at illness onset (mean ± SD) 62 ± 8.26
Disease duration, months (mean ± SD) 27 ± 19.18
Age at sampling (mean ± SD) 65 ± 8.23 57 ± 13.61 58 ± 9.53









The results obtained showed a significant increase of NLRP3 transcriptional levels
in blood samples from ALS patients compared to healthy controls (Figure 4). Although a
decrease was also observed in the OMP group, these differences did not reach a significant
level. Furthermore, comparison of the NLRP3 expression profile with the area under ROC
curves (AUC) was performed to test if NLRP3 gene levels could perform well as a support
for diagnosis tools. AUC results were statistically significant with an area of 0.270 (95%
confidence interval, CI: 0.081–0.459, p = 0.039).
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Figure 4. Transcriptional expression levels of NLRP3 in blood sa ples fro healthy subjects (control),
amyotrophic lateral sclerosis (ALS) patients and patients with other myopathies. Kruskal- allis
tests showed significant differences among ALS patients and the healthy group (p = 0.03). Dunnet’s
post hoc test correction between groups also yielded statistically significant differences between
these groups (p = 0.04). A total of 42 participants were included in this study: 14 control individuals,
14 patients with other myopathies and 14 ALS patients * p < 0.05.
Hence, these results suggested that NLRP3 transcriptional levels in peripheral blood
of ALS patients may be a potential support for diagnosis biomarkers.
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3. Discussion
In recent years, it has been demonstrated that NLRP3 inflammasome plays an impor-
tant role in diverse neurodegenerative diseases; however, its implication in ALS remains
unclear. Thus, our first objective was to study the gene and protein expression of the
NLRP3 inflammasome components in skeletal muscle from WT and SOD1G93A mice
models throughout disease progression.
Upregulation of the inflammasome genes was observed at the asymptomatic stage
(P50) of SOD1G93A mice (Asc, caspase 1 and Il1β were significantly increased), so these
genes may represent potential prognostic and diagnostic biomarkers of ALS (Figure 1A).
However, mRNA abundance did not correlate with protein profile in this stage. Increased
translational levels of inflammasome components were observed at advanced stages of
the disease, which became significant at P120 (Figure 1B). It should be noted that mature
IL1β was only detectable in SOD1G93A animals (Figure 1C), which is in accordance with
previous studies performed in the skeletal muscle of SOD1G93A transgenic rats [14] and
mice [15]. In the last study mentioned, they also analyzed the expression of different NLRs
(NLRP1, NLRC4, NLRP3 and AIM2) and observed elevated levels of NLRC4, and to a
lesser extent NLRP3, in gastrocnemius muscle. This difference with respect to our results in
quadriceps could be explained by the fact that distinct types of skeletal muscle fibers may
express diverse PRRs (including different TLRs and NLRs) in a function of environmental
factors (such as pathogens, inflammatory cytokines and growth factors), so it is possible
that a particular NLR/inflammasome predominates more than others depending on the
muscle [16–18].
Therefore, the results obtained suggest that the progressive activation of NLRP3
inflammasome with the course of the disease could enhance muscle degeneration. This
hypothesis is supported by various studies that have demonstrated that IL1β, after being
activated by NLRP3 inflammasome, plays a crucial role in the onset and disease progression
of several myopathies [19], such as myositis [20], sarcopenia [21] and Duchenne muscular
dystrophy [22,23]. In fact, germline deletion of Nlrp3 in mice led to reduced IL1β serum
levels and protects from inflammation-induced skeletal muscle atrophy [24]. Based on
these findings, our hypothesis that the activation of the NLRP3 inflammasome would
promote muscle degeneration in ALS is reinforced. Hence, NLRP3 may be pointed out as a
possible therapeutic target in ALS skeletal muscle.
Regarding the discrepancy observed between the abundance of protein and mRNA,
this fact is in accordance with several studies that have demonstrated that mRNA levels
are not necessarily predictive for corresponding protein levels [25,26]. Furthermore, con-
sidering the alteration of the RNA metabolism that characterizes ALS pathogenesis, this
result is not surprising. In fact, previous studies of inflammasome in ALS have not seen
agreement between transcriptional and translational levels [9,15].
In view of these findings, our next step was to analyze the prognostic nature of
the NLRP3 inflammasome component’s genes in serial biopsies of skeletal muscle from
SOD1G93A mice. This methodology has already been translated to patients from the
animal model for other candidate biomarkers [27,28].
Nlrp3 transcriptional levels between the early symptomatic (75 days) and symptomatic
(105 days) stages correlated significantly and positively with the longevity of transgenic
mice (r = 0.506, p = 0.027) (Figure 2). This means that the animals that display higher
transcriptional levels of this gene at earlier stages of the disease survive longer. On the
one hand, this finding suggested that Nlrp3 could be a potential prognostic biomarker
of longevity in this animal model. On the other hand, contrary to what our hypothesis
initially expected, NLRP3 would not be completely harmful and could exert a beneficial
function for the muscle at the onset of the disease.
This may be explained by a recently proposed model that defends the notion that aging
or excess nutrients constitute a tipping point to switch NLRP3 function from beneficial to
pathological [29]. This model suggests that the primary physiological function of NLRP3
is to clear noxious substances (such as protein aggregates, a characteristic feature of ALS
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with SOD1G93A and TDP-43Q331K) and to regulate metabolism. However, with age or
earlier in life if there are excess nutrients, NLRP3 becomes pathologic due to too strong of
a response or to macrophage overactivation caused by the chronic presence of excessive
amounts of these harmful substances. Therefore, it has been proposed that this NLRP3
beneficial function in homeostasis could become harmful during the onset of inflammatory
and metabolic diseases, such as multiple sclerosis or Alzheimer’s disease. Interestingly, it
has been seen that mutant proteins SOD1 and TDP-43 activate inflammasome in primary
mouse microglia, accelerating ALS pathogenesis [30,31].
On the other hand, in a murine model of ALS in which neurodegeneration induces
denervation and muscular atrophy, it is possible to think that the activation of the inflam-
masome may have a dual role, as has been described in ALS for its known and powerful
activator, the P2X7 receptor. It has been found that the pharmacological antagonism of P2X7
exerts a positive result in the motor performance of SOD1G93A mice [32] and significantly
prolongs the survival of females [33], while its constitutive deletion anticipates the disease
onset and aggravates its progression [34]. Thus, it has been shown that P2X7 plays a double
role in ALS pathogenesis, and its activation may be beneficial or harmful depending on
the time.
This dual role of inflammasome is consistent with studies performed on other diseases
such as cancer and Alzheimer’s disease, in which despite the fact that the inflammasome
is directly involved in its pathogenesis, there are also reasons to speculate on whether a
moderate degree of its activation could be beneficial, thus being NLRP3 inflammasome a
double-edged sword [29,35–38]. In fact, several studies have shown that the activation of
inflammasome, and therefore caspase 1, has unexpected consequences in certain cell types,
since it not only induces inflammation by activation and secretion of proinflammatory
cytokines, but also regulates levels of extracellular proteins involved in tissue repair and
cytoprotection [29,39–41].
It is important to highlight that only Nlrp3 significantly correlated with longevity, so it
could exert a function, different and independent of inflammasome, that is beneficial for
skeletal muscle. Recent studies have demonstrated that NLRP3 can be imported into the
cell nucleus and act as a transcription factor in Th2 lymphocytes promoting the expression
of IL-4 [42–46]. Interestingly, this anti-inflammatory cytokine is involved in muscle growth
and regeneration [47–49] and, after spinal cord injury, it drives microglia and macrophages
toward a favorable phenotype for tissue repair and functional recovery [50]. In fact, a
recent study has revealed that IL-4 gene therapy in our mouse model delays the onset of
ALS and ameliorates clinical outcomes during the early slowly progressive phase of the
disease [51]. However, such modulation does not produce beneficial effects or reverse
neurodegenerative processes in the late and fast progressing phase of the disease, which
could explain why only the Nlrp3 expression in skeletal muscle correlated with longevity
in the early stages and not at the end.
In addition, it is noteworthy that a recent study has shown that stimulation of the P2X7
axis with an agonist in SOD1G93A mice significantly delays and prevents the denervation
atrophy of skeletal muscles [52]. This finding could support our results about the positive
correlation of Nlrp3 levels and longevity in the earlier stages, since it has been observed that
P2X7 activates NLRP3 through its interaction [53] or the flow of K+ which triggers after its
opening [54]. This produces conformational changes in NLRP3, thus leaving its structure
open and thereby enabling both its translocation into the nucleus and its oligomerization in
the cytoplasm to give rise to the inflammasome assembly. However, other inflammasomes
such as NLRP2, NLRC4, NLRP6 and AIM2 have been seen not to be activated by P2X7,
with the possible exception of NLRP1 and NLRP2 [54]. In view of all this, it is possible that
the muscle improvement observed in SOD1G93A mice after stimulation of P2X7 is closely
related to NLRP3 activation.
For this reason, our next objective was to elucidate whether the activation of NLRP3
is beneficial during the disease progression in this murine model of ALS. To do this, we
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administered MCC950, a small molecule that specifically inhibits NLRP3 by closing its
conformation and driving it toward an inactive state, to 70-day-old mice [12,13].
We observed that mice with inactivated NLRP3 lived less than those that had not
received MCC950 treatment (Figure 3). It should be noted that this difference was greater
especially in the earlier stages, which confirms the stated hypothesis that NLRP3 (either
through the inflammasome or in an independent way) would exert a beneficial function in
ALS pathogenesis particularly at the beginning of the disease. This result could support the
idea that NLRP3 has a favorable function by acting as a transcription factor of IL-4, since
it is in accordance with the previously mentioned gene therapy study with this cytokine
performed on our animal model in which positive effects were observed mainly in the
early slowly progressive phase of ALS [51].
On the other hand, it is possible that over time MCC950 has ceased to have effect on
IL1β levels due to the activation of another NLR member/inflammasome as a compen-
satory response. In fact, it has been observed that in human blood with S. typhimurium
treated with MCC950 there was a sharp decrease in IL1β at the beginning, but after a while
their levels increased again due to the action of NLRC4 inflammasome [55]. This could
explain the fact that in the last stages the difference between treated and untreated animals
is somewhat smaller, since MCC950 might not be acting on the production of IL1β, and thus
the disease pathogenesis would not be ameliorated under this treatment. This idea would
be in accordance with a previous study where it was observed that SOD1G93A-mediated
inflammasome activation (IL1β production) occurs independently of NLRP3, unlike ASC
which was essential [31].
Therefore, the specific inhibition of NLRP3 does not seem to be a good therapeutic
approach for ALS, and it would be better to act at other levels of the pro-inflammatory
cascade of inflammasomes, such as caspase 1, IL1β [31] or all inflammasome components
at once [56].
Based on all these findings, we decided to continue the study of NLRP3 as a promising
biomarker for ALS patients in a less invasive tissue such as peripheral blood, which could
help better the characterization of patients in clinical practice.
We found that NLRP3 transcriptional levels were significantly increased in ALS pa-
tients’ blood with respect to controls, but not compared to other myopathies (Figure 4).
Consequently, NLRP3 may be pointed out as a potential biomarker to support the diagnosis
of ALS patients.
This result is highly relevant since it is very difficult to discover sensitive and spe-
cific ALS biomarkers, which are currently presented as an essential tool for clinical
trials and practice. Generally, the search and discovery of new biomarkers are ham-
pered by the unknown etiopathogenesis of ALS, the great phenotypic variability be-
tween patients and the presence of common characteristics with other myopathies and
neurodegenerative diseases.
Moreover, it is important to highlight the fact that NLRP3 could be a blood-derived
biomarker, since it has the advantage that it can be tested in a non-invasive way and the im-
pact of tissues and systems that are harmed throughout disease progression, such as by neu-
roinflammation, muscle damage or microglial activation, can be monitored concurrently.
Nonetheless, more exhaustive studies with patient samples are required to validate
the diagnostic nature of NLRP3 and even its potential as prognostic biomarker, as we have
seen in the results from our ALS mouse model.
4. Materials and Methods
4.1. Animals
Transgenic mice B6SJL-Tg SOD1G93A were used in this study because they provide a
suitable ALS disease model [57]. These mice express a high copy number of the G93A mu-
tant form of human superoxide dismutase 1 (SOD1) and were purchased from The Jackson
Laboratory (Bar Harbor, ME, USA). The colony was maintained by mating hemizygous
SOD1G93A males with C57BL/6J × SJL/J F1 hybrid females (B6SJLF1) purchased from
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Janvier Labs (Janvier Labs, Le Genest-Saint-Isle, France). The offspring were identified by
PCR amplification of DNA extracted from tail tissue as described in The Jackson Labora-
tory protocol. The mice were housed in a pathogen-free environment under a standard
light/dark (12:12) cycle at the animal facilities in Centro de Investigación Biomédica de
Aragón. Food and water were provided ad libitum.
All experimental procedures were approved by the Ethic Committee for Animal
Experiments from the University of Zaragoza (6 February 2020) and were registered with
the following code number (PI08/20). The care and use of animals were performed in
accordance with the Spanish Policy for Animal Protection RD53/2013 and the EU Directive
2010/63.
4.2. Mouse Tissue Collection
4.2.1. Extraction of Skeletal Muscle Samples in WT and Transgenic SOD1G93A Mice
Hemizygous SOD1G93A mice and age-matched non-transgenic WT control mice at
the early symptomatic (P50), symptomatic (P75) and terminal (P120) stages (n = 4 transgenic
SOD1G93A mice and 4 WT mice, balanced males and females, per stage) were used to
study gene and protein expression throughout disease progression. For this, animals were
euthanized with CO2 and all surgical material was sterilized before dissection. Then,
the Quadriceps femoris was extracted, frozen in liquid nitrogen and stored at −80 ◦C. For
tissue processing, each skeletal muscle sample was pulverized in liquid nitrogen using
a Cellcrusher cryogenic tissue pulverizer (Cellcrusher, Cork, Ireland). Subsequently, the
tissue was divided into two parts, one for the gene study and one for the protein study,
thus reducing the possibility of variation as it was the same animal in the two studies.
4.2.2. Extraction of Biopsies from Skeletal Muscle of SOD1G93A Mice
Twenty SOD1G93A mice were used to study the correlation of gene expression with
longevity (n = 10 mice per sex). For this, we used a methodology validated in our laboratory;
it has already been shown that the results obtained in this animal model are transferable
to patients [27,28]. Animals were anesthetized with isoflurane and three biopsies from
the Gluteus superficialis muscle were obtained per mouse, from a different hind limb each
time, at three different ages that coincided with the early symptomatic stage (75 days),
symptomatic stage (105 days) and terminal stage (endpoint age). The humane endpoint for
these mice was defined as the moment that the animals were unable to right themselves
within 30 s after being placed on their side and the age at this moment was considered
as death for survival analysis [58]. We used the same protocol described in our previous
study [27]. This procedure allowed the study of gene expression in the same animal,
since the Gluteus superficialis muscle (unlike the Quadriceps femoris) is easy to reach and its
manipulation does not prevent the mouse from moving properly after each surgery, so it
was possible to keep the animal alive at different disease stages throughout the study.
4.3. Administration of MCC950
Twenty-seven animals were used in this experiment and were divided into two
groups with balanced sexes: 14 SOD1G93A mice treated with the drug and 13 untreated
SOD1G93A mice. Following the protocol described in a recent study [59], animals received
intraperitoneal injections of sterile PBS (control) or MCC950 (10 mg/kg in PBS) three times
per week from the age of 70 days until death (endpoint age).
4.4. Patients
A total of 42 individuals participated in this study, matched for age and sex when-
ever possible: 14 healthy controls, 14 patients with other myopathies (OMP) and 14 ALS
patients (Table 1).
In all cases written informed consent was obtained according to Declaration of Helsinki
principles and to Directive 2004/23/EC of the European Parliament and of the Council.
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4.5. Blood Samples from Patients
We received blood samples frozen in Pax tubes; the PAXgene Blood RNA Kit (PreAna-
lytiX GmbH, 8634 Hombrechtikon, Switzerland) was used to extract the RNA fraction. In
all samples, the cDNA was also obtained from 1 µg of total extracted RNA (High Capacity
cDNA RT kit; Applied Biosystems, Madrid, Spain).
The analysis of blood samples from Centro Clinico NEMO (Milan, Italy) was approved
by the Research Ethics Committee of the Community of Aragon (7 November 2018) and
was registered with the following code number (PI18/078).
4.6. Gene Expression
For RNA extraction, muscle tissue was homogenized using a PRO200 homogenizer
(PRO Scientific Inc, Oxford, USA). Regarding blood samples, the Blood RNA kit (PreAna-
lytiX GmbH, 8634 Hombrechtikon, Switzerland) was used starting from frozen Pax tubes.
From here, the same protocol was used for samples of animals and patients.
RNA was extracted with TRIzol reagent (Invitrogen, Prat de Llobregat, Spain) and
treated with Turbo DNA-free kit (Ambion, Madrid, Spain) to eliminate genomic DNA.
Once purified, RNA was retrotranscripted using the Superscript First Strand kit (Invitrogen,
Prat de Llobregat, Spain). Quantitative real-time PCR (qRT-PCR) was performed from 1:10
diluted cDNA in triplicates using StepOne Real-Time PCR (Life Technologies; Waltham,
MA, USA). The TaqMan probes (Applied Biosystems, Madrid, Spain) used in this study
are indicated in Table 2.
Table 2. Taqman® Probe and Primer Mixtures Used in Gene Expression Assays.
Gene Symbol Organism Assay ID
NLR family, pyrin domain containing 3 Nlrp3 Mus musculus Mm00840904_m1
PYD and CARD domain containing Pycard Mus musculus Mm00445747_g1
caspase 1 Casp1 Mus musculus Mm00438023_m1
Interleukin 1 beta Il1β Mus musculus Mm00434228_m1
Glyceraldehyde-3-phosphate dehydrogenase Gapdh Mus musculus 4352932E
Actin, beta, cytoplasmic ß-actin Mus musculus 4352933E
NLR family pyrin domain containing 3 NLRP3 Homo sapiens Hs00918082_m1
Glyceraldehyde-3-phosphate dehydrogenase GAPDH Homo sapiens Hs02786624_g1
Hypoxanthine phosphoribosyltransferase 1 HPRT1 Homo sapiens Hs02800695_m1
TATA-box binding protein TBP Homo sapiens Hs00427620_m1
Gapdh and β-actin were used as housekeeping genes for normalization of animal data,
and GAPDH, HPRT1 and TBP were used to normalize patient data. The relative gene
expression was determined using the 2-∆∆CT method [60].
4.7. Protein Expression
For protein extraction, muscle powdered tissue was resuspended in RIPA lysis buffer
containing protease inhibitors (Roche, Basel, Switzerland), homogenated and centrifuged
at 10,000× g for 10 min at 4 ◦C. The supernatant was collected and the protein concentration
was determined by BCA method (Sigma-Aldrich, San Luis, MO, USA). After quantification,
25 µg of protein were loaded to an 8–10% SDS-PAGE and transferred to PVDF membranes
(Amersham™, GE Healthcare Life Sciences, Little Chalfont, UK). For immunodetection,
membranes were blocked with a Tris-buffered saline solution containing 5% skimmed milk
and 0.1% Tween for 1 h at room temperature and then incubated overnight at 4 ◦C with the
selected primary antibodies (Table 3). GAPDH was selected as the normalization protein.
The next day, membranes were washed and incubated with HRP-conjugated anti-rabbit
secondary antibody (sc-2004; Santa Cruz Biotechnology, Quimigen S.L., Madrid, Spain)
for 1 h at room temperature, and the protein bands were visualized using ECL reagents
(GE Healthcare Life Sciences, Little Chalfont, United Kingdom). Densitometry study was
performed using AlphaEase FC software (Bonsai Technologies Group, Madrid, Spain).
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Table 3. Primary Antibodies Used in Protein Expression Assays (Santa Cruz Biotechnology, Quimigen
S.L., Madrid, Spain).
Antibody Host Dilution Reference Number
Cryopyrin (H-66) Rabbit 1:250 sc-66846
ASC (N-15)-R Rabbit 1:250 sc-22514-R
caspase-1 p20 (M-19) Rabbit 1:250 sc-1218-R
IL-1ß (H-153) Rabbit 1:250 sc-7884
GAPDH (FL-335) Rabbit 1:1000 sc-25778
4.8. Statistical Analysis
Comparisons of results obtained in expression studies between the WT and SOD1G93A
groups or between healthy, ALS and other-myopathies patients were made using Student’s
t-test, and Dunnet’s post hoc test was used for statistical correction. The area under ROC
curves (AUC) was calculated to explore the support for diagnosis nature of NLRP3 in
blood samples from healthy, ALS and other-myopathies patients. The Spearman correlation
coefficient was used to determine the linear correlation between transcriptional expression
levels and longevity of SOD1G93A mice. Survival over time was computed using Kaplan–
Meier estimates, and the survival distributions of treated vs. non-treated animals were
tested with the Mantel-Cox log-rank test. The software used for the statistical analysis was
SPSS 22.0 (IBM, Barcelona, Spain). All data represent the means ± standard error of the
mean (SEM). Values were considered statistically significant (*) at p < 0.05 and statistically
highly significant at p < 0.01.
5. Conclusions
In view of the results obtained in the present study, it can be concluded that NLRP3
may be involved in the skeletal muscle pathogenesis of ALS, either through inflammasome
or independently. Inactivation of NLRP3 could not be beneficial to ameliorate disease
progression, but its gene expression might represent a potential biomarker for diagnosis
and prognosis of longevity in skeletal muscle from animal models.
Although further research is needed, this study reveals for the first time that NLRP3
could be useful for diagnostic support in blood samples from ALS patients, which may be
of help in clinical trials and practice.
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Abbreviations
ALS Amyotrophic lateral sclerosis
ASC Apoptosis-associated Speck-like protein containing a CARD
DAMPs Damage-associated molecular patterns
FALS Familial amyotrophic lateral sclerosis
NLR NOD-like receptors
NLRC4 NLR family CARD domain containing 4
NLRP3 NLR Protein 3
NOD Nucleotide-binding oligomerization domain
OMP Other myopathies patients
P2X7 P2X purinoreceptor 7
PAMPs Pathogen-associated molecular patterns
PRRs Pattern recognition receptors
SALS Sporadic amyotrophic lateral sclerosis
SOD1 Superoxide Dismutase 1
TLR Toll-like receptor
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